After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Yahoo Finance discussed the stock recently as it posted Vertex Receives CHMP Positive Opinion for KALYDECO® for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
VRTX belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $433.48 and fluctuated between $434.26 as its day high and $425.70 as its day low. The current market capitalization of Vertex Pharmaceuticals, Inc. is $111.97B. A total of 0.79 million shares were traded on the day, compared to an average of 1.51M shares.
Insider Activity
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, VRTX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 11 BUYs and 102 SELLs from insiders. Insiders purchased 68,791 shares during that period but sold 201,734.
In the most recent transaction, Arbuckle Stuart A sold 3,603 shares of VRTX for 421.77 per share on Feb 21. After the transaction, the EVP, COO now owns 59,439 company shares. In a previous transaction on Feb 21, Sachdev Amit sold 3,191 shares at 421.77 per share. VRTX shares that EVP Chief Patient & Ext Af Off owns now total 60,798.
Among the insiders who sold shares, ALTSHULER DAVID disposed of 3,002 shares on Feb 21 at a per-share price of $421.77. This resulted in the EVP, Global Research and CSO holding 34,022 shares of VRTX after the transaction. In another insider transaction, Atkinson Edward Morrow III sold 1,201 shares at $421.77 per share on Feb 21. Company shares held by the EVP, Chief Technical Ops. Off. now total 18,509.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for VRTX in the last 3 months, the mean price target is $463.81 with high estimates of $578.00 and low estimates of $325.00. In terms of 52-week highs and lows, VRTX has a high of $448.40 and a low of $283.60.
As of this writing, VRTX has an earnings estimate of $4.03 per share for the current quarter. EPS was calculated based on a consensus of 21 estimates, with a high estimate of $4.44 per share and a lower estimate of $3.37. The company reported an EPS of $4.08 in the last quarter, which was 2.80% higher than expectations of $3.97.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. VRTX’s latest balance sheet shows that the firm has $7.52B in Cash & Short Term Investments as of fiscal 2021. There were $967.40M in debt and $2.14B in liabilities at the time. Its Book Value Per Share was $68.22, while its Total Shareholder’s Equity was $10.10B.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for VRTX is Buy with a score of 4.07.
